当前位置:公众访问 >页面
简体中文 / English
1.Screening

group

group B

1.1.Management for Progress
1.2.Inclusion Criteria

recurrent hospitalization due to heart failure caused by volume overload (at least twice in the preceding 12 months)

Yes

heart function cannot be improved or sustained despite of maximal conservative treatment including large dose of diuretics

Yes

the extent of heart failure is assessed as stage III or IV based on the New York Heart Association (NYHA) functional classification

Yes

aged above 18 years

Yes

1.3.Exclusion Criteria

ratio of serum urea to creatinine concentrations is less than or equal to 10

No

estimated glomerular filtration rate (eGFR) calculated by Modification of Diet in Renal Disease (MDRD) equation is less than 10 mL/min/1.73m2

No

patients who suffered from an acute deterioration of heart and/or renal function

No

2.Baseline

triglyceride

2.42 mmol/L

total cholesterol

2.31 mmol/L

Atrial fibrillation

No

Chronic glomerulonephritis

No

Hypertension

No

Idiopathic cardiomyopathy

Yes

Rheumatic heart disease

No

Ischemic cardiomyopathy

No

Insulin

No

Diabetes

No

Ultrasonic echocardiography, UCG

Abnormal with clinical significance

Description in detail for abnormal

left ventricular ejection fractions

32 %

NYHA class

IV级

Urine output

960 ml/day

B-type natriuretic peptide

3107.00 pg/ml

Systolic blood pressure

119 mmHg

Diastolic blood pressure

56 mmHg

Body Mass Index

28.94

Weight

69.10 kg

2.1.Management of the progress
2.2.General information

Residual renal function

16.03 ml/min

BUN/Cr

16.60

eGFR

16.58 ml/min

Statins

Anticoagulation or antiplatelet agents

Name of the drug

2.4.Blood Routine Tests

hemoglobin

80.40 g/L

2.5.Urine and Stool Routine Tests
2.6.Blood Electrolytes Tests
2.7.Coagulation Function Tests
2.8.Serum Liver Function Tests

serum albumin

34.70 g/L

2.9.HBV Markers Test
2.10.Renel Function Test
2.11.Heat Function Examination

QT interval extension

No

2.13.Image Examinations
2.14.Nervous System Examination
2.16.Blood Gas Analysis
2.17.Physical Ability Examination
2.18.Health Relative Quality of Life
3.In the process of the treatment
3.1.Treatment Record

Erythropoiesis-stimulating agents(ESAs)

Yes

Beta blockers

Yes

Diuretics

Yes

RASI(Renin angiotensin system inhibitor)

Yes

4.At the end of the treatment

Prognosis

peritoneal dialysis

Residual renal function

3.50 ml/min

Duration of Peritoneal Dialysis

73 months

Ultrasonic echocardiography, UCG

Abnormal with clinical significance

Description in detail for abnormal

left ventricular ejection fractions

47 %

NYHA class

II级

Peritoneal ultrafiltation

790 ml/day

Urine output

850 ml/day

B-type natriuretic peptide

252.00 pg/ml

4.1.Management for Progress
4.2.Physical examination

systolic pressure

98 mmHg

diastolic pressure

65 mmHg

Weight

61.50 kg

4.3.Blood Routine Tests

hemoglobin

86.30 g/L

4.4.Urine and Stool Routine Tests
4.5.Serum Electrolytes Tests
4.6.Liver Function Tests

serum albumin

34.00 g/L

4.7.HBV Markers Test
4.8.Renel Function Test
4.9.Heat Function Examination
4.10.Image Examinations
4.12.Nervous System Examination
4.14.Blood Gas Analysis
4.15.Physical Sbility Examination
4.16.Health Relative Quality of Life
5.Follow-up 1
6.Follow-up 2
7.Follow-up 3

Other reasons for rehospitalization

Pneumonia
/
Congestive heart failure
/
Hypotension

Catheter related rehospitalization

Tmies of Rehospitalization

4

Bacterial species of peritonitis

Times of peritonitis

0

Technical survival

Yes

Cause of death

Miocardial infarction

Death

Yes

8.Management system of participants
9.Speciman management system
10.Data management system
11.ADR/ADE management system
12.Madicine management system
13.Instruments management system
14.SOPs
14.1.Treatment SOP
14.2.Nursing SOP
14.3.Specimen collection SOP
15.Research team
15.1.Institutions
15.2.Researchers